Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Neuronetics, Inc.
STIM
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $93.9M
$1.41
▲ +4.44%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$0.80 - $4.85
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 60.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- FDA-cleared, clinically-proven transcranial magnetic stimulation technology with established safety profile
- Non-invasive, non-systemic treatment approach reducing medication dependency and side effects
- Established direct sales infrastructure and relationships with psychiatrists and mental health providers
- Proprietary MRI-strength magnetic field technology differentiated from competitor offerings
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Rising prevalence of major depressive disorder and treatment-resistant depression globally
Value
Deep value opportunity - significant discount to Life Sciences Tools peers
Momentum
Weak
-11.2% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying STIM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 4, 2026
MAY 5, 2026
Reported EPS of -$0.16 vs -$0.17 consensus (+5.9% surprise). Revenue of $34.5M vs $34.2M expected (+0.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+5.9%
Next: May 4, 2026
Revenue trend · last 8Q
—
—
+11%
+84%
+132%
+101%
+86%
+8%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$16.4M
$18.5M
$22.5M
$32.0M
$38.1M
$37.3M
$41.8M
$34.5M
Margins · last 8Q
Gross
—
Operating
—
Profit
-31.3%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Canaccord · Mar 19, 2026